REGENXBIO Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- REGENXBIO Inc. (Nasdaq: RGNX) is a clinical-stage biotechnology company that develops, commercializes, and licenses recombinant adeno-associated virus (rAAV) gene therapies for the treatment of rare and debilitating diseases. The company offers a broad pipeline of product candidates across diverse therapeutic areas, including ABBV-RGX-314 for the treatment of wet age-related macular degeneration (AMD) and diabetic retinopathy via suprachoroidal delivery, RGX-121 for the treatment of Hunter syndrome (MPS II), RGX-202 for the treatment of Duchenne muscular dystrophy, and RGX-111 for the treatment of fragile X syndrome; it also provides its NAV Technology platform, which licenses proprietary rAAV vectors and capsids to partners such as AbbVie, Novartis, and Sarepta Therapeutics for use in their gene therapy programs. Founded in 2008 and headquartered in Rockville, Maryland, REGENXBIO operates primarily in the United States with a focus on ophthalmology, neurodegeneration, and metabolic diseases, targeting patients with unmet medical needs in rare genetic disorders. In recent developments, REGENXBIO reported positive 2-year data from its Phase I/II AFFINITY trial of ABBV-RGX-314 in patients with advanced wet AMD, demonstrating sustained vision preservation and reduction in anti-VEGF treatment burden. The company also advanced its RGX-121 program with FDA clearance of an investigational new drug application and initiation of the pivotal INSPIRE trial in 2024, alongside dosing the first pediatric patient. Additionally, REGENXBIO expanded its collaboration with AbbVie through a new license agreement for novel AAV capsids and strengthened its manufacturing capabilities with the completion of a state-of-the-art gene therapy facility in 2024 to support commercial-scale production.
Company News
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of REGENXBIO Inc. (RGNX)
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of REGENXBIO Inc. (RGNX)
RGNX Stock Slumps 25% on FDA Clinical Hold for RGX-121 Gene Therapy
Regenxbio: Sell-Off On Hunter Setback Presents A Risky Buy Opportunity
REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli
REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli
RGNX Investor Notice: Johnson Fistel Investigates REGENXBIO Inc. Following Clinical Hold
Regenxbio Stock Sinks 22% Following Surprise Finding in Gene Therapy Trial
FDA places clinical hold on Regenxbio's gene therapy for Hunter Syndrome
REGENXBIO Announces Regulatory Update on RGX-121 for MPS II
Regenxbio's Multi-Catalyst Setup Is Hard To Ignore (Rating Upgrade)
REGENXBIO Q2 Earnings Call Highlights
REGENXBIO Inc. (RGNX) Q2 2026 Earnings Call Transcript
Regenxbio (RGNX) Beats Q2 Earnings and Revenue Estimates
REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights
REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights
New Strong Sell Stocks for July 23rd
Kuehn Law Encourages Investors of Regenxbio, Inc. to Contact Law Firm
Clinical Trial Results Show Extended Benefits for REGENXBIO Retinal Treatments
REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting